Carregant...
Lenvatinib and radioiodine-refractory thyroid cancers
Over the past decade, several multikinase inhibitors have shown considerable effectiveness against metastatic radioiodine-refractory thyroid cancers in early stage clinical trials. On the basis of some remarkable results in a phase III clinical trial, lenvatinib now joins sorafenib as another multik...
Guardat en:
| Publicat a: | Nat Rev Endocrinol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4518863/ https://ncbi.nlm.nih.gov/pubmed/25824678 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrendo.2015.53 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|